The Journal of Korean Obstetrics and Gynecology (대한한방부인과학회지)

The Society of Korean Medicine Obstetrics and Gynecology (대한한방부인과학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of the Patients and Treatment of Korean Medicine Hospital after Chemotherapy in Patients with Breast Cancer

유방암 환자의 항암화학요법 후 한방병원 입원치료에 대한 일개 한방병원 환자 특성 및 치료 고찰

  • Kang, Su-Jin (Dept. of Korean Medicine Gynecology, College of Korean Medicine, Wonkwang University) ;
  • Kim, Sun-Kyung (Dept. of Korean Medicine Gynecology, College of Korean Medicine, Wonkwang University) ;
  • Yang, Geum-Jin (College of Korean Medicine, Wonkwang University) ;
  • Hong, Ka-Kyung (Dept. of Korean Medicine Gynecology, College of Korean Medicine, Wonkwang University) ;
  • Cho, Han-Baek (Dept. of Korean Medicine Gynecology, College of Korean Medicine, Wonkwang University)
  • 강수진 (원광대학교 한의과대학 한방부인과학교실) ;
  • 김선경 (원광대학교 한의과대학 한방부인과학교실) ;
  • 양금진 (원광대학교 한의과대학) ;
  • 홍가경 (원광대학교 한의과대학 한방부인과학교실) ;
  • 조한백 (원광대학교 한의과대학 한방부인과학교실)
  • Received : 2020.04.16
  • Accepted : 2020.05.29
  • Published : 2020.05.29
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study is to analyse current status and treatment of the Korean medicine hospital after chemotherapy in patients with breast cancer. Methods: We investigated the medical records of 21 patients who admitted to Korean medicine hospital after chemotherapy in patients with breast cacner from March 1, 2017 to December 31, 2019. We searched medical records retrospectively and analyzed current status and treatment of Korean medicine hospital. Results: The average age of 21 participants was 52.81±8.38 years and 40s and 50s accounted for 85.6% of the total. After receiving chemotherapy, the average time to hospitalization was 1.87±3.13days and average hospital stay was 9.78±4.14 days. The subjects were classified as 28.6% of stage I, 52.4% of stage II, 9.5% of stage III, and 9.5% of stage IV. The analysis according to the presence of metastasis was 57.1% without metastasis, 33.3% with axillary lymph node metastasis, and 9.5% with distant metastasis. The main symptoms complained when hospitalized by 21 subjects were nausea (54.2%), fatigue (54.2%), and anorexia (50.8%) in over 50%, pantalgia (47.5%), and insomnia (47.5%), dizziness (44.1%), cold sweating (42.4%), lower extremity pain (40.7%), 37.5~37.9℃ fever (39.0%), headache (37.3%), hot flush (37.3%), pruritus (30.5%) are 30% or more. Korean medicine treatment was performed in 87.4% of all hospitalizations and Gwakhyangjunggi-san-gami was the most administered prescription. Extracts of Korean medicine was performed in 100.0% of all patients and Eunkyo-san was most administered extracts medicine. Acupuncture, moxibustion, and cupping treatments were performed in all 21 study subjects. Other treatments was performed at a frequency of hyperthermia (90.5%), lymph massage (23.8%), air compression therapy (23.8%), and Interference current therapy (19.0%) Conclusion: Korean traditional medicine can be used as a countermeasure for side effects after chemotherapy in breast cancer patients.

Keywords

References

  1. National Cancer Registration Statistics. [cited 2020 Mar 5]. Available from: URL:http//www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=2770
  2. Paik N. Current Status of Breast Cancer in Korea. Ewha Med J. 2014;37(2):69-74. https://doi.org/10.12771/emj.2014.37.2.69
  3. Ahn JH. Systemic adjuvant therapy in breast cancer. Korean J Med. 2005;69(3):243-54.
  4. Park SK. Epidemiological characteristics of breast cancer in Koreans. J Korean Med Assoc. 2019;62(8):424-36. https://doi.org/10.5124/jkma.2019.62.8.424
  5. Broeckel JA, et al. Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2000;62(2):141-50. https://doi.org/10.1023/A:1006401914682
  6. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;2001(30):135-42. https://doi.org/10.1093/oxfordjournals.jncimonographs.a003451
  7. Cassileth BR, et al. The Prevalence of Complementary / Alternative A Systematic Review. Am cancer Soc. 1998;83(4):777-82.
  8. Han S, et al. Experiences of Treatment -Related Side Effects and Supportive Care with Korean Medicine in Women with Breast Cancer - A Focus Group Study. j Korean Obs Gynecol. 2017;30(1):85-94. https://doi.org/10.15204/jkobgy.2017.30.1.085
  9. Park JH, et al. Electroacupuncture for the Treatment of the Chemotherapy -induced Peripheral Neuropathy in Breast Cancer Patient: A Case Report. J Korean Tradit Oncol. 2015;20(1):1-9. https://doi.org/10.15432/JKTO.2015.20.1.001
  10. Han G, et al. A Case Study of a Patient with Breast Cancer Treated with a Combination of Traditional Korean Medicine and Chemotherapy. J Int Korean Med. 2017;38(5):820-7. https://doi.org/10.22246/jikm.2017.38.5.820
  11. Han G, et al. A Case Study of an Advanced Breast Cancer Patient Treated with a Combination of Traditional Korean Medicine and Chemotherapy. J Int Korean Med. 2018;39(2):268-76. https://doi.org/10.22246/jikm.2018.39.2.268
  12. Park B, et al. A Case of Breast Cancer Patient Experiencing Adriamycin Cytoxan and Taxol Side Effects Managed by Traditional Korean Medicine. Korean J Orient Int Med. 2011;32(3):451-7.
  13. Kim SH. Chemotherapy of Breast Cancer. Korean J Med. 2000;58(5):497-509.
  14. Kang E, Kim SW. The Korean hereditary breast cancer study: Review and future perspectives. J Breast Cancer. 2013;16(3):245-53. https://doi.org/10.4048/jbc.2013.16.3.245
  15. Watson GW, Turner RL. Breast cancer; a new approach to therapy. Br Med J. 1959;1(5133):1315-20. https://doi.org/10.1136/bmj.1.5133.1315
  16. Lee A, Moon BI. Chemotherapy in Breast Cancer. Ewha Med J. 2014;37(2):75-82. https://doi.org/10.12771/emj.2014.37.2.75
  17. Park JH, Bae SH, Jung YM. Changes of Symptom Distress and Quality of Life in Breast Cancer Patients Receiving Adjuvant Therapy. Asian Oncol Nurs. 2015;15(2):67-74. https://doi.org/10.5388/aon.2015.15.2.67
  18. Oh SJ. Breast Cancer Facts & Figures. Seoul:Korean Breast Cancer Society. 2019:10.
  19. Kang H, et al. Analysis of the Relationship between Body Mass Index and Breast Cancer Incidence in Korean Women. J Breast Dis. 2016;4(2):64-9. https://doi.org/10.14449/jbd.2016.4.2.64
  20. Charles L, Abram R. Side effects of Adjuvant Treatment of Breast Cancer. N Engl J Med. 2001;344(26):1997-2008. https://doi.org/10.1056/NEJM200106283442607
  21. Saibil S, et al. Incidence of taxaneinduced pain and distress in patients receiving chemotherapy for early-stage breast cancer: A retrospective, outcomes -based survey. Curr Oncol. 2010;17(4):42-7. https://doi.org/10.3747/co.v17i4.562
  22. Joo E. Incidence and Factors Influencing Neutropenia in Patients with Chemotherapy. J Korea Acad Coop Soc. 2018;19(6):519-25.
  23. Jin KP. Taepyeonghyeminhwajegukbang. 1. Beijing:China Press of Traditional Chinese Medicine. 1996:53.
  24. Kim SC, et al. Bangjehak. 4. Seoul: Yeonglimsa. 1999:488-90.
  25. Liu Y, Liu W. Effect of Huoxiangzhengqi Powder on Immune and Metabolic Function of Sub-healthy Animals with Dampness, Spleen and Stomach. Lishizhen Med Mater medica Res. 2011;22(5):1190-2. https://doi.org/10.3969/j.issn.1008-0805.2011.05.071
  26. Liu Y, et al. Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic acid. Evidence-based Complement Altern Med. 2014;2014:1-10.
  27. Viaud S, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971-6. https://doi.org/10.1126/science.1240537
  28. Zitvogel L, et al. Microbiome and Anticancer Immunosurveillance. Cell. 2016;165(2):276-87. https://doi.org/10.1016/j.cell.2016.03.001
  29. Routy B, et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15(6):382-96. https://doi.org/10.1038/s41571-018-0006-2
  30. Viaud S, et al. Gut microbiome and anticancer immune response: Really hot Sh*t! Cell Death Differ. 2015;22(2):199-214. https://doi.org/10.1038/cdd.2014.56
  31. Oh KT. Onbyeongjobyeon. 1. Seoul: Jipmundang. 2004:94-9.
  32. Kim SC, et al. Bangjehak. 4. Seoul: Yeonglimsa. 1999:83-4.
  33. Li Z. Immune-Regulating Effect of Yinqiao Powder in Different Decocted Time on Rats with Immune Suppression. J Tradit Chinese Med. 2008;49(12):1112-5.
  34. Fu YJ, et al. Effects of different principles of Traditional Chinese Medicine treatment on TLR 7/NF-${\kappa}B$ signaling pathway in influenza virus infected mice. Chin Med. 2018;13(1):1-16. https://doi.org/10.1186/s13020-017-0157-6
  35. Dundee JW, et al. Acupuncture prophylaxis of cancer chemotherapy-induced sickness. J R Soc Med. 1989;82(5):268-71. https://doi.org/10.1177/014107688908200508
  36. Molassiotis A, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: A pragmatic randomized controlled trial. J Clin Oncol. 2012;30(36):4470-6. https://doi.org/10.1200/JCO.2012.41.6222
  37. Ben-Horin I, et al. Acupuncture and Reflexology for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer. Integr Cancer Ther. 2017;16(3):258-62. https://doi.org/10.1177/1534735417690254